Related Experiment Video
Updated: May 13, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Pexelizumab and survival in cardiac surgery
1Deptartment of Interventional Cardiology, Istituto Clinico S. Ambrogio, Milan, Italy.
Insights
Pexelizumab, a complement inhibitor, may reduce mortality in coronary artery bypass grafting patients. Further research into anti-inflammatory strategies for cardiopulmonary bypass is warranted.
Area of Science:
- Anesthesiology
- Immunology
- Cardiovascular Surgery
Background:
- An international consensus conference discussed strategies to reduce mortality in cardiac anesthesia and intensive care.
- Pexelizumab, a monoclonal antibody targeting complement component 5, was considered an ancillary therapy for cardiac surgery.
- The drug is no longer available, but the underlying concept remains relevant.
Purpose of the Study:
- To summarize the consensus conference's findings regarding pexelizumab in cardiac surgery.
- To evaluate the evidence supporting pexelizumab's potential to reduce mortality.
- To highlight the need for further investigation into anti-inflammatory approaches in cardiopulmonary bypass.
Main Methods:
- Review of an international consensus conference proceedings.
- Analysis of a subgroup analysis from a meta-analysis of randomized controlled trials.
- Audience voting data from the consensus conference.
Main Results:
- A meta-analysis subgroup suggested pexelizumab might reduce mortality in coronary artery bypass grafting patients up to 6 months post-surgery.
- Pexelizumab was not prioritized by the consensus conference audience, receiving insufficient votes.
- The drug is currently off the market.
Conclusions:
- While pexelizumab is unavailable, the principle of mitigating the inflammatory response during cardiopulmonary bypass warrants continued research.
- Investigating novel anti-inflammatory strategies remains crucial for improving outcomes in cardiac surgery.
- The consensus highlights the gap in evidence and acceptance for specific immunomodulatory therapies in this setting.
Abstract:
A recent international consensus conference on the reduction in mortality in cardiac anesthesia and intensive care included pexelizumab, a recombinant monoclonal antibody to the component 5 of the complement system, among the ancillary (i.e. non-surgical) drugs/techniques/strategies that might influence survival rates in patients undergoing cardiac surgery. The consensus conferences state that "A subgroup analysis of a meta-analysis of randomized controlled trials suggested that pexelizumab might reduce mortality (longest follow up available, up to 6 months) in patients undergoing coronary artery bypass grafting. Pexelizumab was not included among the most important topics of the consensus conference as it was the only topic that did not receive a sufficient percentage of votes from the audience (32% at the first round and 35% at the second round). Pexelizumab is no longer on the market, however, the concept of reducing the generalized inflammatory process accompanying cardiopulmonary bypass deserves further investigation.
